FDA notified providers and patients that they are continuing to review available data suggesting an increase in the risk of diabetes, heart attack, stroke, and sudden death in men treated with gonadotropin-releasing hormone agonists as androgen deprivation therapy for prostate cancer.
On May 3, 2010, FDA notified providers and patients that they are continuing to review available data suggesting an increase in the risk of diabetes, heart attack, stroke, and sudden death in men treated with gonadotropin-releasing hormone (GnRH) agonists as androgen deprivation therapy (ADT) for prostate cancer.
GnRH agonists including leuprolide acetate, sold under the brand names Lupron (Abbott), Viadur (Bayer), and Eligard (Sanofi-aventis), goserelin acetate (Zoladex, AstraZeneca), triptorelin pamoate (Trelstar, Watson), histrelin acetate (Vantas, Endo Pharmaceuticals), and nafarelin acetate (Synarel, Pfizer) suppress the production of testosterone, a hormone that is involved in the growth of prostate cancer. Consequently, such agents shrink or slow the growth of prostate tumors.
According to FDA, a number of administrative claims- or registries-based observational studies have "reported small, but statistically significant increased risks of diabetes and/or cardiovascular events in patients receiving GnRH agonists." Specifically, the agency references 6 studies evaluating patients undergoing ADT to treat prostate cancer versus patients not undergoing this treatment. However, the agency cautions that "these studies have design limitations that make it difficult to confirm a cause and effect relationship."
Patients are being urged not to stop their treatment with GnRH agonists unless told to do so by their provider.
SOURCES
FDA. FDA Drug Safety Communication: Ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certain cardiovascular diseases. May 3, 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm209842.htm. Accessed May 10, 2010.
Levine GN, D'Amico AV, Berger P, et al; on behalf of the American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association. Circulation. 2010;121:833–840.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More